NICE Knockback For BMS Immunotherapy Opdivo In Lung Cancer
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb Co.'s immunotherapy Opdivo (nivolumab) is not cost-effective and should not be provided for NHS patients with lung cancer in England and Wales, according to draft guidance from the health technology assessment body NICE. BMS had offered a confidential discounting scheme to reduce the cost below its list price of £5,200 per month (for a patient weighing 73kg), but this failed to sway the National Institute for Health and Care Excellence.
You may also be interested in...
BMS' Opdivo Is Too Expensive, Says NICE
NICE has again said no to Bristol-Myers Squibb's Opdivo, this time for locally advanced or metastatic non-squamous non-small-cell lung cancer in adults already treated with chemotherapy. The company had suggested different pricing proposals to try and make the drug more cost-effective, but it may fare better if it focuses on certain patient populations.
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.